14-day Premium Trial Subscription Try For FreeTry Free

Explanation to Bollinger's Bands

Bollinger Bands was created by John Bollinger in the early 1980s, its purpose is to define price action relative to the assets highs and lows. This technical indicator is used to identify buy and sell signals and has proven very well in doing so.

Bollinger Bands consist of a set of three curves drawn in relation to securities prices. The middle band is a measure of the intermediate-term trend, usually a simple moving average, that serves as the base for the upper and lower bands. The interval between the upper and lower bands and the middle band is determined by volatility, typically the standard deviation of the same data that were used for the average. StockInvest.us uses Bollingers suggested 20 day average.

Middle Bollinger Band = 20-period simple moving average
Upper Bollinger Band = Middle Bollinger Band + 2 * 20-period standard deviation
Lower Bollinger Band = Middle Bollinger Band - 2 * 20-period standard deviation

BandWidth defines the current width of the band.
%b defines the current position within the band.

BandWidth = (Upper Bollinger Band - Lower Bollinger Band) / Middle Bollinger Band
%b = (Last - Lower Bollinger Band) / (Upper Bollinger Band - Lower Bollinger Band)

Live Samples:

Bollinger Bottleneck Buy Pattern 1
Bollinger Bottleneck Buy Pattern 2
Bollinger Bottleneck Sell Pattern

Bottlenecks in bandwidth indicate an upcoming change. Break up through the moving average line or continuous movements above the moving average line indicate a break up, and vice versa.

Source: http://www.bollingerbands.com

RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of INZY
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Green day on Wednesday for Inozyme Pharma, Inc. stock after gaining 4.54%
(Updated on May 01, 2024)

Sell candidate since Apr 08, 2024 Loss -21.47% PDF

The Inozyme Pharma, Inc. stock price gained 4.54% on the last trading day (Wednesday, 1st May 2024), rising from $4.41 to $4.61. During the last trading day the stock fluctuated 8.39% from a day low at $4.35 to a day high of $4.72. The price has fallen in 6 of the last 10 days and is down by -0.86% for this period. Volume fell on the last day by -128 thousand shares and in total, 501 thousand shares were bought and sold for approximately $2.31 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies in the lower of a very wide and falling trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $4.26 is broken, it will firstly indicate a stronger fall rate. Given the current short-term trend, the stock is expected to fall -12.55% during the next 3 months and, with a 90% probability hold a price between $3.73 and $6.36 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

INZY Signals & Forecast

There are mixed signals in the stock today. The Inozyme Pharma, Inc. stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at $5.56. On a fall, the stock will find some support from the short-term average at $4.43. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). A buy signal was issued from a pivot bottom point on Thursday, April 25, 2024, and so far it has risen 6.47%. Further rise is indicated until a new top pivot has been found. Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and it may be an early warning. The stock should be watched closely.

Support, Risk & Stop-loss for Inozyme Pharma, Inc. stock

Inozyme Pharma, Inc. finds support from accumulated volume at $4.41 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". During the last day, the stock moved $0.365 between high and low, or 8.39%. For the last week, the stock has had daily average volatility of 6.03%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (INZY) For The Upcoming Trading Day Of Thursday 2nd

For the upcoming trading day on Thursday, 2nd we expect Inozyme Pharma, Inc. to open at $4.56, and during the day (based on 14 day Average True Range), to move between $4.25 and $4.97, which gives a possible trading interval of +/-$0.364 (+/-7.89%) up or down from last closing price. If Inozyme Pharma, Inc. takes out the full calculated possible swing range there will be an estimated 15.78% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $4.41 (4.34%) than the resistance at $5.24 (13.67%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Inozyme Pharma, Inc. stock A Buy?

Inozyme Pharma, Inc. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Current score: -2.070 Sell Candidate Unchanged

Predicted Opening Price for Inozyme Pharma, Inc. of Thursday, May 2, 2024

Fair opening price May 2, 2024 Current price
$4.56 ( 1.12%) $4.61

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for INZY

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 4.92 6.80 %
R2 4.78 3.77 %
R1 4.70 1.90 %
Current price: 4.61
Support S1 4.42 -4.15 %
S2 4.33 -6.01 %
S3 4.19 -9.04 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 5.74 24.51 %
R2 5.48 18.87 %
R1 5.24 13.67 %
Current price 4.61
Support S1 4.41 -4.34%
S2 4.40 -4.56%
S3 4.39 -4.77%

FAQ

What is the symbol for Inozyme Pharma, Inc. Stock and on which exchange is it traded?
The symbol for Inozyme Pharma, Inc. is INZY and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Inozyme Pharma, Inc. Stock?
Inozyme Pharma, Inc. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

How to buy Inozyme Pharma, Inc. Stock?
Inozyme Pharma, Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Inozyme Pharma, Inc. Stock.

What's the current price of Inozyme Pharma, Inc. Stock?
As of the end of day on the May 01, 2024, the price of an Inozyme Pharma, Inc. (INZY) share was $4.61.

What is the 52-week high and low for Inozyme Pharma, Inc. Stock?
The 52-week high for Inozyme Pharma, Inc. Stock is $7.79 and the 52-week low is $2.69.

What is the market capitalization of Inozyme Pharma, Inc. Stock?
As of the May 01, 2024, the market capitalization of Inozyme Pharma, Inc. is 284.769M.

When is the next earnings date for Inozyme Pharma, Inc.?
The upcoming earnings date for Inozyme Pharma, Inc. is May 14, 2024.
Click to get the best stock tips daily for free!

About Inozyme Pharma, Inc.

Inozyme Pharma. Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for spec... INZY Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT